EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Effect of Intravenous Tirofiban Versus Placebo on Excellent Outcome in Patients With Acute Ischemic Stroke: The Multicenter, Randomized INSTANT Trial Protocol

Fan Zhang iD, Minghui Xiao, Cong Zhang iD, Guangxiong Yuan iD, Zhiyong Xie, Yi Yin, Ruize Zhou, Shanggui Yuan, Genxiang Xiao, Donghuan Mei iD, Xiaobing Zeng, Huashi Liu und 15 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.038536 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Fan Zhang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Ganzhou People's Hospital Ganzhou China. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Ischemic Stroke, Platelet Aggregation Inhibitors, Tenecteplase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is common that symptoms do not improve or even worsen after intravenous thrombolysis (IVT) in acute ischemic stroke. However, it remains unknown whether early administration of tirofiban after IVT may improve clinical outcomes. This trial aims to assess the efficacy and safety of early administration of tirofiban after IVT with tenecteplase in acute ischemic stroke during the 90‐day follow‐up period after treatment.

Methods

The INSTANT (Intravenous Tenecteplase and Tirofiban for Acute Ischemic Stroke) trial is an investigator‐initiated, randomized, placebo‐controlled, double‐blind, multicenter trial. In the study, 310 patients with acute nonlarge/medium‐sized vascular occlusion and nonatrial fibrillation stroke who are treated with intravenous tenecteplase will be consecutively randomized to intravenous tirofiban or placebo in a 1:1 ratio over 2 years across 50 intravenous thrombolysis‐capable stroke centers in China. In addition, eligible subjects will receive best medical treatment according to national guidelines. The primary efficacy end point is excellent functional status, defined as a score of 0 or 1 on the modified Rankin Scale at 90 days after randomization. Safety outcomes include symptomatic intracranial hemorrhage within 48 hours and mortality at 90 days.

Conclusions

The INSTANT trial was designed to determine the role of tirofiban within 24 hours after IVT in patients with acute ischemic stroke. Our primary objective is to investigate whether the early administration of tirofiban following IVT can enhance the proportion of patients exhibiting no or minimal symptoms post acute ischemic stroke. Registration URL: ChiCTR2300074368; Unique Identifier: www.chictr.org.cn .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsIschemic StrokePlatelet Aggregation InhibitorsTenecteplaseThrombolytic TherapyTirofibanAgedFemaleHumansMaleMiddle AgedAdministration, IntravenousChinaDouble-Blind MethodMulticenter Studies as TopicRandomized Controlled Trials as TopicTime FactorsTreatment Outcome

Stichwörter der Autor:innen

acute ischemic strokeexcellent outcomeintravenous thrombolysisprotocolrandomized trialtenecteplasetirofiban

Substanzen

Fibrinolytic AgentsPlatelet Aggregation InhibitorsTenecteplaseTirofiban

Autor:innen und Institutionen

  • Ganzhou People's Hospital Ganzhou China.
  • People's Hospital of Wan'an City Wan'an China.
  • Xiangtan Central Hospital Xiangtan China.
  • People's Hospital of Yudu City Yudu China.
  • People's Hospital of Shangyou City Shangyou China.
  • People's Hospital of RuiJin City RuiJin China.

ORCID-Profile: Fan Zhang, Cong Zhang, Guangxiong Yuan, Donghuan Mei, Qingqing Fu, Bin Li, Jinxing Lai, Wei Sun, Shuhua Xie, Zhaohui Lai, Zhongming Qiu, Zidian Jiang, Xianghong Liu, Guoyong Zeng

Zitieren

APA

Zhang, F., Xiao, M., Zhang, C., Yuan, G., Xie, Z., Yin, Y., Zhou, R., Yuan, S., Xiao, G., Mei, D., Zeng, X., Liu, H., Li, H., Liu, H., Tan, J., Chen, B., Fu, Q., Li, B., Lai, J., …, & INSTANT investigators (2025). Effect of Intravenous Tirofiban Versus Placebo on Excellent Outcome in Patients With Acute Ischemic Stroke: The Multicenter, Randomized INSTANT Trial Protocol. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.038536

Vancouver

Zhang F, Xiao M, Zhang C, Yuan G, Xie Z, Yin Y, et al. Effect of Intravenous Tirofiban Versus Placebo on Excellent Outcome in Patients With Acute Ischemic Stroke: The Multicenter, Randomized INSTANT Trial Protocol. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.038536

BibTeX
@article{Zhang2025,
  author = {Zhang, Fan and Xiao, Minghui and Zhang, Cong and Yuan, Guangxiong and Xie, Zhiyong and Yin, Yi and Zhou, Ruize and Yuan, Shanggui and Xiao, Genxiang and Mei, Donghuan and Zeng, Xiaobing and Liu, Huashi and Li, Huadong and Liu, Hongwen and Tan, Jinchang and Chen, Bin and Fu, Qingqing and Li, Bin and Lai, Jinxing and Sun, Wei and Xie, Shuhua and Lai, Zhaohui and Qiu, Zhongming and Jiang, Zidian and Liu, Xianghong and Zeng, Guoyong and INSTANT investigators, INSTANT investigators},
  title = {Effect of Intravenous Tirofiban Versus Placebo on Excellent Outcome in Patients With Acute Ischemic Stroke: The Multicenter, Randomized INSTANT Trial Protocol},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.038536}
}
Kostenlos starten →